Novostia announces that it raised CHF6.5m from private investors to advance its disruptive aortic and mitral heart valve to clinical trials.
Image: Novostia has raised capital to advance its disruptive aortic and mitral heart valve to clinical trials. Photo: courtesy of rajcreationzs / FreeDigitalPhotos.net.
Heart valve diseases affect more than 100 million people worldwide. Every year hundreds of thousands of patients undergo a heart valve replacement. Available technologies entail serious constraints: lifelong anticoagulant medication or further replacements due to limited valve durability.
Thanks to a unique patented design and the use of a high-performance biocompatible polymer, Novostia eliminates all these constraints as well as clicking noises.
“Our technology should significantly improve the quality of life of people bearing a heart valve prosthesis, especially kids and young patients, while reducing overall healthcare costs. We appreciate the trust and support of our investors and look forward to bringing this long-awaited innovation to the patients and the physicians,” said Geoffroy Lapeyre, Novostia CEO.
Novostia is a privately held medical device company incorporated in 2017 in Microcity Neuchâtel, Switzerland, developing an innovative artificial heart valve.
Source: Company Press Release